Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Vaccines and Diagnostics S.r.l
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
To assess the reactogenicity of MenACWY-CRM and MenACWY-TT vaccines, given to healthy toddlers at 12-15 months of age, as measured by the percentage of subjects with at least one severe solicited AE r...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
Study to evaluate the immunogenicity and safety of Twinrix, Engerix-B and Havrix when administered with Menveo
Immunogenicity Objectives: Primary To establish the non-inferiority of hepatitis A/B vaccine with MenACWY-CRM as compared to hepatitis A/B vaccine without MenACWY-CRM, measured by geometric mean ti...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
A Phase 3b, Randomized, Open-label, Multi-Center Study Assessing Immunogenicity, Safety and 1 Year Persistence of Antibodies after One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Healthy Children 2 to 10 years of age. Több vizsgálóhelyre tervezett klinikai vizsgálat az immunogenitás, a biztonságosság értékelésére egy vagy két adag agyhártyagyulladás elleni Novartis (Meningococcus ACWY) oltóanyag, 2-10 éves egészséges gyermekeknél történő alkalmazása után
Immunogenicity objectives: Primary 1. To assess the immunogenicity of either one or two doses of MenACWY-CRM vaccine (given 2 months apart) when administered to healthy children 2 to 5 years of age,...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
A Phase 2 Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a new Novartis Meningococcal B Recombinant Vaccine evaluating the immunogenicity, tolerability and safety when given concomitantly with routine vaccines in 2-month-old infants
Immunogenicity Objectives To assess if any of seven different formulations of rMenB+OMV NZ or rMenB (no OMV) vaccine induce sufficient immune response when given to healthy infants at 2, 3 and 4 month...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and non-Adjuvanted Egg-derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects from 6 Months to 17 Years of Age
To identify the preferred vaccine formulation (with or without MF59), dosage (of antigen and adjuvant) and schedule (one or two administrations) of the egg-derived H1N1sw monovalent vaccine in healthy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above
Immunogenicity Objective To evaluate the antibody response to each influenza vaccine antigen after vaccination with the TIV vaccine, as measured by single radial hemolysis (SRH) or hemagglutination ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2010-2011, when Administered to Elderly Subjects
Primary To evaluate the antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) at 21 days post-immunization in elderly subjects in compliance with the requ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadjuvanted inactivated subunit influenza vaccine, when administered to adults affected by chronic diseases
Immunogenicity Objective To compare the immunogenicity of a single intramuscular (IM) injection of FLUAD™ (FLUAD) vs. inactivated subunit virus influenza vaccine, with regards to A/H3N2 antigen, when...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
A Phase III, Randomized, Open-label, Single-center Study to Evaluate the Safety and Immunogenicity of a FLUAD-H5N1 Influenza Vaccine in Adult Subjects Using Four Different Vaccination Schedules
To evaluate the magnitude of antibody responses to two doses of FLUAD-H5N1 influenza vaccine, each containing 7.5µg of A/H5N1 antigen administered 1, 2, 3, or 6 weeks apart. To evaluate the safety a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Vaccines and Diagnostics S.r.l
MAJ Il y a 5 ans
A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered with Routine Infant Vaccinations to Healthy Infants
The consistency of the three commercial lots will be demonstrated first, prior to combining the data from the three lots to evaluate overall immunogenicity following three doses of rMenB+OMV NZ. -To...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant